Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome
Release Date: 06/11/2026
Lab Minute: Human Prion Disease
Neurology Minute
In this lab minute, Dr. Stacey Clardy discusses human prion disease.
info_outline
Lab Minute: Human Prion Disease
Neurology Minute
In this lab minute, Dr. Stacey Clardy discusses human prion disease.
info_outline
July 2026 President Spotlight: Mid-Year Update
Neurology Minute
In the July episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost provide a mid-year review of the AAN’s progress, highlighting advocacy successes and the growing momentum for brain health worldwide. Stay informed by watching the video.
info_outline
Preparing ALS Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants
Neurology Minute
Dr. Derek Stitt and Dr. Jennifer Morganroth discuss why identifying carrier status is so important. Show citation: Morganroth J, Yasek J, Harms M. Preparing Amyotrophic Lateral Sclerosis Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants. Neurol Genet. 2026;12(4):e200406. Published 2026 Jun 24. doi:
info_outline
When Drug Marketing Masquerades as Clinical Trials
Neurology Minute
Dr. Justin Abbatemarco and Sukhun Kang discuss seeding trials and other hidden marketing tactics in clinical trials, and their implications for clinical practice and patient care. Show citation: Kang S, Lin I, Ekblom M, and Chang S. Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients. The Conversation. 2026;6(5). doi:
info_outline
The DRAIN Trial
Neurology Minute
Dr. Margarita Fedorova discusses the DRAIN trial and the efficacy of acetazolamide in idiopathic normal pressure hydrocephalus. Show citation: Virhammar J, Fasth O, Ekblom M, et al. Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2026;25(6):550-559. doi:
info_outline
Diagnosis and Management of Headache
Neurology Minute
Dr. Matthew Robbins discusses the assessment and diagnosis of headache in emergency settings, emphasizing red and green flags to differentiate primary from secondary headaches. This episode provides practical tips for trainees and clinicians to improve headache management. Show citation: Robbins MS. Diagnosis and Management of Headache: A Review. JAMA. 2021;325(18):1874-1885. doi:
info_outline
Navigating the Transition From Pediatric to Adult Epilepsy Care - Part 2
Neurology Minute
In the second episode of this series, Dr. Dara Albert and Dr. Scott Perry discuss common barriers to transitioning from pediatric to adult care and share practical strategies clinicians can use to support successful patient transitions. Show citation: Perry MS, Nascimento FA, Pina-Garza JE, et al. Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States: A Narrative Review. Neurol Clin Pract. 2026;16(3):e200616. doi:
info_outline
Neurology® at 75: The Evolution of the Neurology Journal
Neurology Minute
To celebrate 75 years of Neurology®, Dr. Chris Boes and Dr. José Merino discuss the journal’s history, its evolution, and what lies ahead for the future of Neurology®. Read more about the first .
info_outline
Navigating the Transition From Pediatric to Adult Epilepsy Care - Part 1
Neurology Minute
In part one of this series, Dr. Dara Albert and Dr. Scott Perry discuss what every neurology resident should know about caring for young adults with epilepsy as they transition from pediatric to adult neurology. Show citation: Perry MS, Nascimento FA, Pina-Garza JE, et al. Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States: A Narrative Review. Neurol Clin Pract. 2026;16(3):e200616. doi:
info_outlineDr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.
Read more about this abstract on the AAN website.
Show transcript:
Dr. Shuvro Roy:
Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results?
Dr. Amanda Piquet:
So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment.
Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly.
Dr. Shuvro Roy:
Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so?
Dr. Amanda Piquet:
Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process.
Dr. Shuvro Roy:
Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.